- Advertise
- Contact Us
- Editorial Info
- Contribute
- Terms and Conditions
- Privacy Policy
- Do not sell my Personal Information
© 2022 MJH Life Sciences™ and Rheumatology Network. All rights reserved.
Rheumatoid Arthritis
The Rheumatology Network rheumatoid arthritis clinical focus page provides information on the latest rheumatoid arthritis news, study and clinical trial findings, and clinical guideline updates. We feature expert interviews with leading physicians and investigators, articles, videos, podcasts, and breaking FDA approvals for rheumatoid arthritis drugs.
Patients with Autoimmune Disease at Greater Complications Risk Following Heart Attack
September 14, 2022
Investigators believe that coronary intervention, intensified medical therapy, and an aggressive risk factor optimization approach should be available to patients with rheumatic disease presenting with myocardial infarction whenever possible.
No Increased Risk of Insulin Resistance in Prednisone-Exposed Fetuses
August 31, 2022
Long-term corticosteroids during pregnancy is associated with maternal and fetal adverse outcomes which may influence the insulin resistance later in life.
Low-Dose Methotrexate Exposure Minimally Increases Risk of Melanoma
August 31, 2022
"Comprehensively defining the risk of melanoma associated with low-dose methotrexate is important for clinicians across several medical disciplines."
Machine Learning Predicts TNF Inhibitor Response in RA
August 30, 2022
Machine learning algorithms identify patterns without being explicitly programmed to do so, which allows for unbiased discoveries.
Cardiology Co-Management May Reduce Hospitalization Rates, Adverse Events in RA
August 24, 2022
"Cardiovascular manifestations in rheumatoid arthritis can be complex, raising concerns for adequate patient management and provider-dependent roles.”
Interstitial Lung Disease Increases Mortality Risk in RA
August 23, 2022
Investigators believe that “screening for comorbidities of COPD and diabetes mellitus with end-organ damage as part of the routine in treating RA-ILD population" may be beneficial.
FDA Approves Citrate-Free, High-Concentration Adalimumab Biosimilar Adalimumab-bwwd
August 17, 2022
The US Food and Drug Administration approved of the citrate-free, high-concntration (100 mg/mL) formulation of adalimumab-bwwd, a biosimilar of adalimumab, for the treatment of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, plaque psoriasis, and ankylosing spondylitis.
Higher Rates of Infection Reported in Tofacitinib vs TNFi in RA
August 05, 2022
Rates of serious and non-serious infection events were higher in patients receiving tofacitinib, 5 mg 2 times daily and 10 mg 2 times daily, when compared with TNFis.
COVID-19 Booster Improves Humoral, Cellular Immunogenicity in SLE, RA
July 29, 2022
Although a third dose of mRNA vaccine significantly increased antireceptor-binding domain (RBD) titer in a previous study, clinical factors associated with the immunogenicity in immunosuppressed populations have not been adequately studied.
COVID-19 Negatively Impacted Emotional and Social Wellbeing in Patients with RA
July 28, 2022
The top 5 themes identified surrounded fear as the dominant emotion, social connections and work, physical health, self-identity, and self-management as a way of coping.